Elevai Labs Inc (ELAB) News

2000000000 is pre merge. Post merge it would be 10 million. So net authorized would become 12.5 million total final.

Also isn't the authorized increase not be until the merger with PMGC Holdings Inc is complete and the Re-Domestication is put into effect?

As stated in another DEFR14C released on 11/25/2024:
Principal Features of the Re-Domestication

The Re-Domestication will be effected by the merger (the “Merger”) of Elevai Labs Inc. with and into PMGC Holdings Inc., a wholly owned subsidiary of Elevai Labs Inc. that will be incorporated under Nevada law for the purposes of the Merger. PMGC Holdings Inc. will be the surviving corporation in the Merger and will continue under the name “PMGC Holdings Inc.” Elevai Labs Inc. will cease to exist as a result of the Merger.

The Merger will not become effective until the Merger Agreement or an appropriate certificate of merger is filed with the Secretary of State of the State of Nevada and the Secretary of State of the State of Delaware, which will not take place until at least 20 days after the mailing of this Information Statement to our shareholders.

At the effective time of the Merger, the Nevada Articles, the Nevada Bylaws and Nevada law will govern our corporation’s operations and activities. However, there are no substantial differences in the Nevada Articles and Nevada Bylaws from the Delaware Certificate and Delaware Bylaws.

Upon completion of the Merger, each outstanding share of Common Stock will be converted into one share of common stock, $0.0001 par value per share, of PMGC Holdings Inc. As a result, the existing shareholders of Elevai Labs Inc. will automatically become shareholders of PMGC Holdings Inc. (Nevada), Elevai Labs Inc. will cease to exist and PMGC Holdings Inc. will continue to operate our business under the name “PMGC Holdings Inc.” Elevai Labs Inc. stock certificates will be deemed to represent the same number of PMGC Holdings Inc. shares as were represented by such Elevai Labs Inc. stock certificates prior to the Re-Domestication.

You will not have to take any action to exchange your stock certificates as a result of the Merger. The current certificates representing shares of the Company’s common stock will automatically represent an equal number of shares of PMGC Holdings Inc.’s common stock following the Re-Domestication.

Upon completion of the Re-Domestication, the authorized capital stock of PMGC Holdings Inc. will consist of 2,000,000,000 shares of common stock, $0.0001 par value, and 500,000,000 shares of preferred stock, $0.0001 par value, which is identical to the authorized capital stock of Elevai Labs Inc.

The Re-Domestication will not result in any change to our daily business operations or the present location of our principal executive offices in Newport Beach, California. The financial condition and results of operations of PMGC Holdings Inc. immediately after the consummation of the Re-Domestication will be identical to that of Elevai Labs Inc. immediately prior to the consummation of the Re-Domestication. In addition, at the effective time of the Merger, the directors of PMGC Holdings Inc. will be Braeden Lichti, Graydon Bensler, Jeffrey Parry, Juliana Daley, George Kovalyov and Jordan Plews. Currently, Graydon Bensler serves as our Chief Executive Officer and Chief Financial Officer and he will serve in the same capacities for PMGC Holdings Inc. Our directors and majority shareholders have already approved the forms of Merger Agreement, Nevada Articles and Nevada Bylaws, copies of which are attached as exhibits to this Information Statement.

Little bit confused as to the 10-Q(third quarter) and the DEFR14C released 11/25/2024 discussing the authorized share increase...the 10Q says that the AS is 300 million but the 14C says it will be changed from 375 million current....where did the extra 75 million shares come from since September 30th?

As stated in 10Q:

14. Equity

Common Stock

Authorized
As of September 30, 2024, and December 31, 2023, the Company had 300,000,000 common stock authorized, each having a par value of $0.0001.

Issued and outstanding

As of September 30, 2024, and December 31, 2023, the Company had 49,376,039 and 17,329,615 shares issued and outstanding, respectively.

And what it says in the 14C:
The Written Consent:

1. approved an amendment to our Certificate of Incorporation to increase the total number of authorized shares (the “Increase in Authorized Shares”) from three hundred seventy-five million (375,000,000) shares to two billion five hundred million (2,500,000,000) shares, consisting of two billion (2,000,000,000) shares of common stock and five hundred million (500,000,000) shares of preferred stock (the “Approval of Certificate of Incorporation Amendment for Increase in Authorized Shares”).

Imagine both being announced a couple of days apart....approval EL22 and no change from 375 million authorized....or vice versa.

Two major announcements to push price up are pending
1.Fed approval in EL22
2. No authiriEd shares increase

Well. it didn't give a kick but it still seems to be holding onto the $2 mark.

Elevai Labs Inc. Subsidiary, Elevai Skincare, Launches S-Series Root Renewal System, Marking Entry into Hair Care Market
December 06 2024 - 7:30AM


ELEVAI Labs Inc. (Nasdaq: ELAB) (“Elevai” or the “Company”), a diversified holding company, announces the launch of the S-Series Root Renewal System™ (the “Root Renewal System”), a revolutionary entry into the hair care market by its wholly owned subsidiary, Elevai Skincare Inc. (“Elevai Skincare”). The Root Renewal System is a three-part hair and scalp care system consisting of a shampoo, conditioner and serum that combines the latest in patent pending exosome and mitochondrial technology to target scalp and hair health at the cellular level.
This launch reflects Elevai Skincare’s ongoing commitment to science-driven, results-oriented innovations.

The Root Renewal System will be initially introduced through key medical aesthetics partners in select accounts across the United States. This phased rollout strategically positions the product as a premium offering ahead of the full launch, including e-commerce sales, in January 2025. Visit www.ElevaiSkincare.com for more information.


Exclusive Technologies and Groundbreaking Results

The Root Renewal System incorporates two proprietary technologies that, when combined, offer unparalleled results for scalp and hair health:

Elevai PREx Exosomes™: Nano-encapsulated growth factors protected by a lipid bilayer that support dormant hair follicles and overall scalp health.
Y100™ by Yuva Biosciences: An AI-discovered small molecule that supports mitochondrial function, which can result in increased cellular energy to rejuvenate hair follicles. BosleyMD® has lauded the Y100 technology as “one of the biggest innovations in hair loss we’ve seen in twenty-five years,” marking its first successful application in their new product line1.
“This system is a testament to our commitment to advancing the science of hair and scalp health,” said Dr. Jordan R. Plews, Chief Executive Officer of Elevai Skincare. “By combining our proprietary PREx Exosomes with Yuva Bio’s Y100 mitochondrial technology, we’ve developed a dual-mechanism solution that promotes follicle rejuvenation and scalp vitality. This groundbreaking synergy is backed by research and designed to deliver transformative results.”


The Root Renewal System builds upon ongoing research conducted by Elevai Skincare in partnership with Carly Klein, President of National Hair Loss Medical Aesthetics. Previous studies demonstrated the effectiveness of Elevai’s proprietary exosome technology in hair restoration, showing promising results in reversing hair thinning, reducing the signs of scalp inflammation, and promoting the recovery of dormant or miniaturized hair follicles.

Positioned for Market Leadership

“This launch marks a pivotal milestone for Elevai Skincare as its first new product launch since its current two and only products were launched in 2022, reflecting the strategic push for additional revenue streams under Elevai Labs’ new leadership,” said Graydon Bensler, Chief Executive Officer of Elevai Skincare parent company, Elevai Labs. “The Root Renewal System adds a breakthrough product to Elevai Skincare’s portfolio, addressing growing demand in the high-growth hair care market. The Skincare sales team will be leveraging their strong relationships in the medical aesthetics space to position this product for early success, with a broader consumer rollout planned for January 2025. This launch not only strengthens Elevai Skincare’s product offering but also creates significant new opportunities for growth and profitability.”

Breakthrough status🚀🚀🚀🚀🚀

Again, another day of holding ground.

Is that a promise?

Tomorrow morning news will be monstrous

This is indeed good news....
https://elevaiskincare.com/products/root-renewal-system

Generally it take a day or two market to respond to positive news especially post split stocks. Friday is the day ti see a spike.

2.40 AHs?

LOL...3 minutes later...
Back out $2.28 for a flip. Will revisit again
Back in $1.97-$1.99 round 2

Soaking up the float for a major move

Micro Rna nobel prize in the house

from website one of their products
bought some this morning...shares that is...
Ingredients
Human Umbilical Mesenchymal Stem Cell Conditioned Media, Water (Aqua), Glycerin, Aloe Barbadensis Leaf Juice, Hydroxyethylcellulose, Hydrolyzed Sodium Hyaluronate, Sodium Hyaluronate, Bis(tripeptide-1) Copper Acetate, Polysorbate 20, Polysorbate 60, Ceramide NP, Ceramide AP, Ceramide EOP, Acetyl Octapeptide-3, Palmitoyl Tripeptide-37, Palmitoyl Tripeptide-1, Palmitoyl Tetrapeptide-7, Acetyl Hexapeptide-8, Trifluoroacetyl Tripeptide-2, Dextran, Pullulan, Arginine, Glutathione, Yeast Extract, Nannochloropsis Oculata Extract, Camellia Sinensis Leaf Extract, Citrullus lanatus (Watermelon) Fruit Extract, Pyrus Malus (Apple) Fruit Extract, Lens Esculenta (Lentil) Fruit Extract, Sodium PCA, Sodium Lactate, Sodium Phytate, Leuconostoc/Radish Root Ferment Filtrate, Caprylyl Glycol, Ethylhexylglycerin, Phytosphingosine, Cholesterol, Sodium Lauroyl Lactylate, Carbomer, Xanthan gum, Phenoxyethanol, Hexylene Glycol, Butylene Glycol, Disodium Phosphate, Sodium Phosphate, Sodium Benzoate, Potassium Sorbate

Add $1.87s

Back in $1.97-$1.99 round 2 

Back out $2.28 for a flip. Will revisit agin

This is holding well post split....I thought today's news was pretty good.

mhmm

Traded half of float premarket $2.02

Some premarket movement. New float about 2m..
Added $1.98 again

When it is expected? Any estimated time for fast track approval?

FDA Fast track explosion

What the hell going on? I am averaged at $5. Any chances of life?

Nuclear bots going to activate with news AH

They can’t fool us anymore with the bots in short action, Pharma whales going to take bits

Power hour Live The Dream Squeeze

Shorts going to be thought a lesson of a lifetime

Fuck you short criminals, God damn you fucked everyone good till you meet your match to rock and roll

Clan confirmed 3M Outstanding

These short fuckers love to rape retail, well i’m about to get real angry with my clan and clean up the shop

These fuckers love to rape their shareholders

Not even a dead cat bounce for heavens sake, they just brought us to the cleaners after they raped us

Christ what the fuck is going on!!

Grabbed a few down here $2.11 watching for a bigger dip

Don’t sell!!!lock up your shares!!!

Lock up your shares, bull stampede is imminent

They are getting desperate for shares, all holding for massive evaluations

Burn in hell dirty rat short scumbags of the earth

It's a short rat trap, the dirty rat scumbags of the earth will swim in rats vomit

All hold for multi dollars

Pound it now bulls, send it!!!!!!

The dip is in going into strong hands

Big Slaps hitting

$2.63 is first resistance wall

🔥🔥SHORTS TURNED LONG🔥🔥